Stock research
HUMAW Humacyte, Inc.
Healthcare • Biotechnology
Humacyte, Inc. is a company dedicated to the creation and production of bioengineered human tissues that are readily available and suitable for implantation. These advanced tissues are intended for the treatment of a...…
Humacyte, Inc. is a company dedicated to the creation and production of bioengineered human tissues that are readily available and suitable for implantation. These advanced tissues are intended for the treatment of a variety of diseases and medical conditions, applicable to numerous anatomical sites and therapeutic areas. The company employs its distinct, proprietary scientific platform to engineer and manufacture human acellular vessels (HAVs). A significant advantage of these HAVs is their capacity to be implanted into patients without triggering an adverse immune response or leading to rejection by the body. Humacyte is actively developing a diverse portfolio of HAVs, aiming to address needs within the vascular repair, reconstruction, and replacement market. This encompasses uses in cases of vascular trauma, establishing arteriovenous access for hemodialysis, treating peripheral arterial disease, performing pediatric heart surgery, and executing coronary artery bypass grafting. Additionally, their technology supports the delivery of cellular therapies, such as pancreatic islet cell transplantation for managing Type 1 diabetes. Established in 2004, Humacyte, Inc. is headquartered in Durham, North Carolina.
1Y change
-97.96%
Range high
$0.50
Congress · 90d
0
Insiders · 90d
0
Public signal layer
Who is disclosing activity in HUMAW?
Price
Showing 1Y history. Source: FMP historical price full.
- Prev Close
- $0.01
- Day High
- $0.23
- Day Low
- $0.01
- 52w High
- $0.23
- 52w Low
- $0.01
- Volume
- 514,447
- Avg Volume
- Beta
- 2.517
* TTM/most recent where available
Company
- Ticker
- HUMAW
- Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- CEO
- Laura E. Niklason
- Employees
- 184
- Website
- humacyte.com
Key Metrics
- Market Cap
- 12M
- P/E
- P/B
- P/S
- EV/EBITDA
- ROE
- Net Margin
- Div Yield
- FCF/Share
* TTM/most recent where available
DCF Valuation
Standard DCF
Levered DCF
Market Price
DCF vs Price (30D window)
Price uses last 30 days; DCF line holds latest value across the window.DCF line = solid green (latest value repeated across window), Price = dashed blue (daily closes).